Metraipolis › archive › dc_5e38552ef1bc

Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based… — Europe PMC PMID:41267986

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41267986
DOI
10.3389/fonc.2025.1709336
License (as archived)
solo-consultazione
Archived
2026-11-08T19:02:38.882Z
SHA-256 of the archived text
bc384f04a0860cb5180dded5902273077eb75b05884cf3124cb8101e7c47bd27
Stable URL of this page
https://metraipolis.com/documento/dc_5e38552ef1bc

How to cite

Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based… — Europe PMC PMID:41267986 — Europe PMC (en), https://europepmc.org/article/MED/41267986 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5e38552ef1bc (Metraipolis archive dc_5e38552ef1bc, sha256 bc384f04a0860cb5180dded5902273077eb75b05884cf3124cb8101e7c47bd27)
BibTeX
@misc{dc5e38552ef1bc,
  title = {Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based… — Europe PMC PMID:41267986},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41267986},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5e38552ef1bc; sha256 bc384f04a0860cb5180dded5902273077eb75b05884cf3124cb8101e7c47bd27},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41267986. Agents can read the archived copy with the MCP tool read_document.